Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucerastat monotherapy versus placebo in adults with Fabry disease
NL-OMON50474Phase 3Active, not recruiting
- Sponsor
- Idorsia
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fabry disease (FD) comparing Lucerastat with Placebo (2 arms). Primary endpoint: Change from baseline to Month 6 in modified BPI-SF3 neuropathic pain score. Started Sep 2018; status: active, not recruiting.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NL-OMON50474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50474.